Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Observational

Automated and Reliable Estimation of Patient Height From CT Scan Using an Artificial Intelligence Algorithm

NCT07864857 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-11-01
Last updated
2026-10-15

Condition(s) studied

Patient With an Appointment for an Abdominal CT Scan and Able to Stand up for Height Measurement

Study summary

The TAILLE study is a single-center, non-interventional (RIPH3), uncontrolled, non-randomized, open-label study.prospective study conducted at CHU Grenoble Alpes.

The goal is to evaluate the reliability of an AI algorithm developed as part of the TAILLE-pilot study to estimate height from abdominal CT scan data and relevant clinical data like age and gender.

The TAILLE-pilot study , is a pilot data study (RNIPH) aimed at developing artificial intelligence algorithms using a retrospective cohort, developed by our team. It is based on AI algorithms trained to predict height from abdominal CT scan volumes.

The TAILLE study therefore aims to prospectively evaluate the performance of this algorithm in a new cohort of adult patients scheduled for an abdominal CT scan. The TAILLE study hypothesize that height can be reliably estimated using this algorithm, potentially with greater accuracy at the individual level than self-reported height, the limitations of which have been documented in the literature.

As part of the TAILLE study, three methods will be compared of height estimation or measurement :

* CRA-measured height: height measured by a Clinical Research Associate (CRA), serving as the reference method;
* AI-estimated height: height estimated by the AI algorithm developed as part of the TAILLE-pilot study;
* Self-reported height: height reported by the patient.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient with a scheduled appointment for an abdominal CT scan in the Radiology Department of CHUGA * Patient able to stand for height measurement * Patient who does not object to participating in the study * Patient affiliated with a social security Exclusion Criteria: * Patient with amputation of at least one limb * Patient with metallic hardware in the spine (artifact) * Protected person referred to in Articles L1121-5 to L1121-8 of the Code of Public Health

Primary outcome measure(s)

  • Assessment of the reliability of an AI algorithm developed as part of the TAILLE-pilot study to estimate height from abdominal CT scan and relevant clinical data, such as gender and sex — At enrollement
    Assessment of the differences between CRA-measured height and AI-estimated height (CRA = Clinical Research Associate). CRA-measured height is the reference

Trial sites (1)

FacilityCityRegionStatus
University Hospital CHU Grenoble Alpes Grenoble France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07864857 on ClinicalTrials.gov ↗ ← All trials in France